By Andrew Spiegel, CEO, Colon Cancer Alliance
The Patriot-News

The lead article in this month’s New England Journal of Medicine was a perspective piece written by key Food and Drug Administration officials on the development of America’s biosimilars program. Biosimilars are the imitative versions of biologic medicines, the miracle drugs to treat serious conditions such as cancer, multiple sclerosis and early Alzheimer’s disease.

As a founder and current CEO of the Colon Cancer Alliance, a patient advocacy group dedicated to helping colon cancer patients, I read the NEJM article intently. I know firsthand that a lot is at stake – for patients, medical practitioners, state legislators and innovation. I have personally witnessed cancer’s devastating effects and felt the hope associated with the development of new, innovative medicines.

Read More